---
created: 2025-04-13
updated: 2025-04-13T10:53
id: Qhe8`9Ks0G
specialty: immuno
specialty_id: 210
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::03-recombinant-cytokines-&-clinical-uses
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::03-recombinant-cytokines-&-clinical-uses::bone-marrow-stimulation::epo
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::07-immunology
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::immunology-&-biochemistry-pharmacology::immuno-stimulants-&-biochemistry-pharmacology::immunostimulants-(cytokine-therapy,interferons)
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::11000-11999::11945
  - source/ak-step1-v11::^other::^expn::bgadd
  - source/ak-step1-v11::^other::^expn::uworld
  - source/ak-step1-v11::^other::^fa-updates::fa2018
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield"
type: flashcard
---

# Question
The most common side effect of erythropoetin stimulating agents is **hypertension**

---

# Answer
possibly due to activation of EPO receptors on vascular endothelial and smooth muscle cells